Samsung Bioepis Co., Ltd., on June 8th, announced that the company has entered into a license, development and commercialisation agreement with NIPRO Corporation for multiple biosimilar candidates, including SB17, an ustekinumab biosimilar candidate, in Japan.
Under the terms of the agreement, Samsung Bioepis will be responsible for the development, manufacture and supply of the medicines, while NIPRO will be responsible for the commercialisation of the medicines in Japan.
“This partnership marks an important step towards expanding our footprint in Japan. Biosimilars have a great potential to bring cost savings and widen access to treatments for healthcare systems, providers, and patients in Japan. We look forward to collaborating with NIPRO, a company renowned for its high-quality medical devices and healthcare solutions, to accelerate access to treatments in the Japanese market,” said Kyung-Ah Kim, President and Chief Executive Officer of Samsung Bioepis. “We will continue to advance our development platform and innovate access to treatments for healthcare systems, payers, physicians, and patients around the world.”
More related news:
Celltrion’s Infliximab Biosimilar, becomes Remdantry in Canada
Merck Signs MoU with KAIST to Further Scientific Partnership in South Korea
Seaport Therapeutics Winds Up USD 225Mn Series B Financing Round
